文献速递其他结缔组织病

利妥昔单抗联合吗替麦考酚酯治疗系统性硬化症合并原发性心脏受累且对环磷酰胺难治的患者:10例回顾性探索性分析

Combination therapy of rituximab and mycophenolate in patients with systemic sclerosis and primary cardiac involvement refractory to cyclophosphamide: a retrospective exploratory analysis of 10 cases.
PubMed 文献 · RMD Open · 2025-06-10

本研究回顾性分析10例系统性硬化症相关原发性心脏受累且对环磷酰胺脉冲治疗难治的患者,接受利妥昔单抗(每3-6个月1000 mg)联合吗替麦考酚酯(至多3000 mg/天)治疗。随访6-12个月期间,所有患者血浆肌钙蛋白T持续下降(p=0.0020),6例左室射血分数降低者中5例改善3%-23%,可评估的6例室性早搏均减少(p=0.0313),9例NT-proBNP升高者中6例下降,改良Rodnan皮肤评分显著降低(p=0.0020)。长期随访至6年记录7例严重不良事件(5例感染、2例致死事件)。作者认为该联合方案可能有效,但需对照前瞻性研究进一步证实。

要点

  • 利妥昔单抗联合吗替麦考酚酯治疗后,所有10例患者血浆肌钙蛋白T持续下降(p=0.0020)。
  • 6例左室射血分数降低者中5例改善3%-23%,可评估的6例室性早搏均减少(p=0.0313)。
  • 长期随访至6年记录7例严重不良事件,包括5例感染和2例致死事件。

核心结论

  • 作者认为利妥昔单抗联合吗替麦考酚酯可能改善系统性硬化症患者对环磷酰胺难治的心脏表现。
  • 作者指出需要对照前瞻性研究进一步证实这些初步观察结果并证明该联合方案的长期安全性。

研究设计与样本

  • 本研究为在本中心进行的回顾性病历分析,纳入10例系统性硬化症相关原发性心脏受累且对既往环磷酰胺脉冲治疗难治的患者。
  • 原发性心脏受累定义为肌钙蛋白T升高且至少符合以下一项心脏表现:右或左心室收缩或舒张功能障碍、心肌炎、心包炎、心脏传导阻滞或室性心律失常。
  • 对环磷酰胺脉冲治疗后心脏受累加重或持续存在的患者,接受利妥昔单抗(每3-6个月1000 mg)联合吗替麦考酚酯(至多3000 mg/天)治疗。
  • 心脏结局在6-12个月随访期内评估。

主要发现

  • 联合治疗开始后,所有患者血浆肌钙蛋白T水平持续下降(p=0.0020)。
  • 6例左室射血分数降低的患者中5例左室射血分数改善3%至23%。
  • 所有可评估患者(n=6)室性早搏发生率下降(p=0.0313)。
  • 9例N末端脑钠肽前体水平升高患者中6例下降。
  • 改良Rodnan皮肤评分显著降低(p=0.0020)。

关键数值与推荐

  • 原发性心脏受累定义:肌钙蛋白T升高且至少一项心脏表现(右或左心室收缩或舒张功能障碍、心肌炎、心包炎、心脏传导阻滞或室性心律失常)。
  • 利妥昔单抗剂量为每3-6个月1000 mg,吗替麦考酚酯剂量为至多3000 mg/天。
  • 心脏结局评估随访期为6-12个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the high mortality risk, no specific treatment options for cardiac manifestations in systemic sclerosis (SSc) currently exist. We performed a retrospective medical records analysis at our centre to explore the therapeutic effects of a combination therapy with rituximab (RTX) and mycophenolate (MMF) in 10 patients with SSc-related primary cardiac involvement refractory to previous primary treatment with cyclophosphamide (CP).SSc-related primary cardiac involvement was defined as the presence of troponin T elevation and of at least one of the following cardiac manifestations: right or left ventricular systolic or diastolic dysfunction, myocarditis, pericarditis, heart blocks or ventricular arrhythmias. Patients who had worsening or persistence of cardiac involvement after CP pulse therapy received a combination therapy of RTX (1000 mg every 3-6 months) and MMF (up to 3000 mg/day). Cardiac outcomes were evaluated during a 6-12-month follow-up period.Following the initiation of the combination therapy, consistent decreases in plasma levels of troponin T were observed in all patients (p=0.0020). Corresponding to this, left ventricular ejection fraction (LVEF) improved between 3% and 23% in five of the six patients with reduced LVEF, the rate of ventricular extrasystoles declined in all assessable patients (n=6, p=0.0313) and N-terminal pro hormone of brain natriuretic peptide decreased in six of the nine patients with elevated levels. Significant reductions in modified Rodnan skin score were also observed (p=0.0020). RTX/MMF combination was generally well tolerated. In the long-term follow-up period of up to 6 years, seven serious adverse events consisting of five infections and two fatal events were recorded.Our findings suggest that combination therapy with RTX and MMF may be an effective approach for improving refractory cardiac manifestations in patients with SSc. Controlled and prospective studies are required to further substantiate these encouraging observations and to prove the long-term safety of RTX/MMF combination.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Adjailia EB, Grasshoff H, Schinke S, et al. Combination therapy of rituximab and mycophenolate in patients with systemic sclerosis and primary cardiac involvement refractory to cyclophosphamide: a retrospective exploratory analysis of 10 cases. RMD Open. 2025. PMID: 40499976. doi:10.1136/rmdopen-2025-005493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。